Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 160Thoracic 151Gynecologic 150Gastrointestinal 63Genitourinary 16Head & Neck 14Tumor-Agnostic 7Dermatologic 5Sarcoma 4Other solid neoplasm 2Other 1Endocrine 1Classical hematology 1

Conditions

Carcinoma, Ovarian Epithelial 1Anemia 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13Cytarabine 9Dalteparin 8Rivaroxaban 7Daunorubicin 7apixaban 6Etoposide 6Methotrexate 5Idarubicin 5Heparin, Low-Molecular-Weight 5Cyclophosphamide 5emicizumab 4Tinzaparin 4Thioguanine 4Mitoxantrone 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Enoxaparin 4pegfilgrastim 3hetrombopag 3epoetin beta 3Saline Solution 3Radiotherapy 3Hydrocortisone 3Erythropoietin 3Dexamethasone 3Aspirin 3Asparaginase 3telapristone acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Paclitaxel × Classical hematology × Clear all
NCT00189371 2005-09-19

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

AGO Study Group

Phase 3 Terminated
300 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡